Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences, Inc. (RNA) Short term Debt (2019)

Avidity Biosciences' Short term Debt history spans 1 years, with the latest figure at $2.8 million for Q4 2019.

  • For Q4 2019, Short term Debt changed N/A year-over-year to $2.8 million; the TTM value through Dec 2019 reached $2.8 million, changed N/A, while the annual FY2019 figure was $2.8 million, N/A changed from the prior year.
  • Short term Debt reached $2.8 million in Q4 2019 per RNA's latest filing.
  • In the past five years, Short term Debt ranged from a high of $2.8 million in Q4 2019 to a low of $2.8 million in Q4 2019.